Fertility and Quality of Life after Treatment for Testicular Cancer

2002 ◽  
pp. 213-214
Author(s):  
R. A. Huddart ◽  
A. Norman ◽  
C. Moynihan ◽  
D. Coward ◽  
J. Nicholls ◽  
...  
2005 ◽  
Vol 14 (3) ◽  
pp. 251-259 ◽  
Author(s):  
J. Fleer ◽  
H. J. Hoekstra ◽  
D. T. Sleijfer ◽  
M. A. Tuinman ◽  
E. C. Klip ◽  
...  

2020 ◽  
Vol 6 (4) ◽  
pp. 711-719 ◽  
Author(s):  
Mikkel Bandak ◽  
Jakob Lauritsen ◽  
Christoffer Johansen ◽  
Michael Kreiberg ◽  
Julie Wang Skøtt ◽  
...  

2018 ◽  
Vol 118 (10) ◽  
pp. 1313-1321 ◽  
Author(s):  
Scott C Adams ◽  
Darren S DeLorey ◽  
Margie H Davenport ◽  
Adrian S Fairey ◽  
Scott North ◽  
...  

2012 ◽  
Vol 22 (2) ◽  
pp. 369-378 ◽  
Author(s):  
Bernhard Holzner ◽  
Fabio Efficace ◽  
Umberto Basso ◽  
Colin D. Johnson ◽  
Neil K. Aaronson ◽  
...  

2014 ◽  
Vol 31 (7) ◽  
Author(s):  
Ahmet Alacacioglu ◽  
Eda Ulger ◽  
Umut Varol ◽  
Tugba Yavuzsen ◽  
Murat Akyol ◽  
...  

2014 ◽  
Vol 44 (8) ◽  
pp. 813-817 ◽  
Author(s):  
B. O'Carrigan ◽  
M. Fournier ◽  
I. N. Olver ◽  
M. R. Stockler ◽  
H. Whitford ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21607-e21607 ◽  
Author(s):  
Michal Chovanec ◽  
Lucia Vasilkova ◽  
Lucia Setteyova ◽  
Katarina Rejlekova ◽  
Jana Obertova ◽  
...  

e21607 Background: Testicular cancer (GCT) survivors are at risk for different types of late treatment sequelae. This study aimed to evaluate long-term quality of life (QOL), sexual (SexF) and cognitive functioning (CogF) issues resulting from cisplatin-based chemotherapy. Methods: QoL, SexF and CogF data were prospectively collected in 83 GCT survivors with median 9 year follow-up (range 5-32). The chemotherapy group (CTG) consisted of 53 and 18 patients receiving a cisplatin cumulative dose of ≤ 400mg/m2 (LCD) and > 400mg/m2 (HCD), respectively. The control group (CG) included 12 patients treated with orchiectomy (6 pts) and adjuvant radiotherapy (6 pts). Data were collected using EORTC QLQ-C30, QLQ-TC26, FACT-Cog and sexual functioning questionnaires and analyzed according to the scoring guidelines. Results:The CTG survivors had significantly (all p < 0.05) more limitations while working or doing daily activities (37% vs 8%), needed to rest more often (61% vs 33%) and feared the disease relapse more often (73% vs 50%) compared to the CG. A subscale for family problems within QLQ-TC26 have shown higher impairment in the CTG vs. CG (mean score ± SEM: 54.2 ± 26.7 vs. 38.8. ± 7.3, P < 0.05). Cognitive abilities were perceived better in CG vs. CTG (mean score 24.5 ± 1.8 vs. 20.5 ± 0.7, P < 0.05). The CG surivors had higher education level and fathered more children compared to the CTG. The CTG felt more unsettled than the CG (all P < 0.05), however the impact of perceived cognitive impairment on their lives did not significantly differ ( P = 0.4). Patients who received HCD have suffered from dyspnea more often than patients treated with LCD (mean dyspnea subscale score ± SEM: 22.2 ± 4.4 vs 8.9 ± 2.6, P < 0.05). The HCD group also reported more difficulties to concentrate while watching television/reading newspaper and struggled to name things during conversation compared with the LCD group ( P < 0.05 for both). No impairment in sexual functioning was reported. Conclusions: Our study shows thatGCT survivors cured with cisplatin-based chemotherapy suffered from QoL issues and their perception of cognitive abilities was altered. The HCD of cisplatin further impaired several QoL and cognitive aspects.


2013 ◽  
Vol 7 (4) ◽  
pp. 630-640 ◽  
Author(s):  
Michael A. Hoyt ◽  
Stefan J. Cano ◽  
Christopher S. Saigal ◽  
Annette L. Stanton

2017 ◽  
Vol 14 (1) ◽  
pp. S66
Author(s):  
M. Kurobe ◽  
T. Suetomi ◽  
K. Kawai ◽  
K. Tanaka ◽  
A. Ikeda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document